trial

Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order

NCTId NCT00282165
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 8 (actual)
Sponsored by UMC Utrecht
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
8 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2006-11
Primary completion
2012-12
Eligibility
MALE · 18 Years · 65 Years

Interventions & indications

Drugs
naratriptan

Sponsors

UMC UtrechtLead Sponsor
FPC De Kijvelanden, PoortugaalCollaborator

Investigators

5
Frank Koerselman, MD, PhDStudy Chair
Rob L. van Ojen, MD, PhDStudy Director
Henk Nijman, PhDStudy Director
Berend Olivier, PhDStudy Director
Adriano van der Loo, MDPrincipal Investigator

Sites

1 total
Poortugaal, Netherlands

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE4
Primary Completion Date
2012-12
Status
TERMINATED
relationships
The graph out of here
drug
naratriptan
drug
lead_sponsor
UMC Utrecht
company
collaborator
FPC De Kijvelanden, Poortugaal
company
indication
Intermittent Explosive Disorder
indication
Psychotic Disorders
indication
Antisocial Personality Disorder
indication
investigator
Frank Koerselman, MD, PhD
person
Rob L. van Ojen, MD, PhD
person
Henk Nijman, PhD
person
Berend Olivier, PhD
person